Viridian Therapeutics, Inc. VRDN Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s total liabilities?
- Viridian Therapeutics, Inc. (VRDN) reported total liabilities of $12.5M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s total liabilities changed year-over-year?
- Viridian Therapeutics, Inc.'s total liabilities decreased by 77.9% year-over-year, from $56.51M to $12.5M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s total liabilities has grown at a 12.3% compound annual growth rate (CAGR), from $11.22M to $20.03M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.